Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

@article{Younes2012PanobinostatIP,
  title={Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.},
  author={Anas Younes and Anna Sureda and Dina Ben-Yehuda and Pier Luigi Zinzani and Tee-Chuan Ong and H Miles Prince and Simon J Harrison and Mark H Kirschbaum and Patrick Johnston and Jennifer A Gallagher and Christophe Le Corre and Angela Shen and Andreas Engert},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 18},
  pages={2197-203}
}
PURPOSE Hodgkin's lymphoma (HL) has no standard of care for patients who are relapsed or refractory to autologous stem-cell transplantation (ASCT). This phase II study examined safety and activity of panobinostat in this population. PATIENTS AND METHODS Panobinostat 40 mg was administered orally three times per week. The primary end point was objective response rate (ORR) based on investigator assessment of radiologic imaging. Secondary end points included ORR by independent central review… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 101 extracted citations

Similar Papers

Loading similar papers…